JAK2 and myeloproliferative disorder: JAK2–JAK2V617F—This is a point mutation of the JAK2 gene and results in myeloproliferative disorders with a polycythemia-like phenotype and increased erythropoietin-independent red blood cell production and splenomegaly [67].